64 related articles for article (PubMed ID: 1538951)
21. GM-CSF-mediated impairment of liver to synthesize albumin, cholinesterase, and cholesterol.
Takahashi M; Nikkuni K; Moriyama Y; Shibata A
Am J Hematol; 1991 Mar; 36(3):213-4. PubMed ID: 1996559
[TBL] [Abstract][Full Text] [Related]
22. Hematopoietic growth factors for the treatment of myelodysplastic syndromes.
Hast R; Bernell P
Acta Haematol Pol; 1991; 22(2):203-7. PubMed ID: 1726768
[No Abstract] [Full Text] [Related]
23. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
Stasi R; Pagano A; Terzoli E; Amadori S
Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II study with GM-CSF in patients with myelodysplastic syndromes.
Hoelzer D; Ganser A; Greher J; Völkers B; Walther F
Behring Inst Mitt; 1988 Aug; (83):134-8. PubMed ID: 3071328
[TBL] [Abstract][Full Text] [Related]
25. Hemophagocytosis exacerbated by G-CSF/GM-CSF treatment in a patient with myelodysplasia.
Wang S; Degar BA; Zieske A; Shafi NQ; Rose MG
Am J Hematol; 2004 Dec; 77(4):391-6. PubMed ID: 15551287
[TBL] [Abstract][Full Text] [Related]
26. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
27. Effects of granulocyte-macrophage colony-stimulating factor in iatrogenic myelosuppression, bone marrow failure, and regulation of host defense.
Gutterman J; Vadhan-Raj S; Logothetis C; Anaissle E; Estey E; Talpaz M; Kurzrock R
Semin Hematol; 1990 Jul; 27(3 Suppl 3):15-24. PubMed ID: 2198660
[TBL] [Abstract][Full Text] [Related]
28. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO
Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099
[TBL] [Abstract][Full Text] [Related]
29. Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group.
Gerhartz HH; Visani G; Delmer A; Zwierzina H; Ribeiro M; Jacobs A; Marcus R; Baumelou M; Fière D; Labar B
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():36-7. PubMed ID: 2697397
[No Abstract] [Full Text] [Related]
30. Is granulocyte-macrophage colony-stimulating factor (GM-CSF) safe in myelodysplastic syndromes?
Mittelman M; Floru S; Pick AI
Haematologia (Budap); 1994; 26(2):111-5. PubMed ID: 7890261
[TBL] [Abstract][Full Text] [Related]
31. [GM-CSF can reveal a latent infection].
Bastion Y; Coiffier B; Tigaud JD; Bryon PA
Presse Med; 1991 Mar; 20(10):477-8. PubMed ID: 1827183
[No Abstract] [Full Text] [Related]
32. [Increase of neopterin after treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF)].
Melichar B; Solichova D; Jebavy L
Presse Med; 1994 Mar; 23(12):581. PubMed ID: 8066063
[No Abstract] [Full Text] [Related]
33. Granulocyte-macrophage colony-stimulating factor gene in myelodysplastic syndromes.
Karlic HI; Weber E; Schlögl E; Krieger O; Lutz D
Am J Hematol; 1991 Jan; 36(1):79-80. PubMed ID: 1984690
[No Abstract] [Full Text] [Related]
34. Clarifications to the standard neutrophil response criteria for clinical trials in myelodysplastic syndromes are needed.
Steensma DP; Letendre L; Tefferi A
Blood; 2001 May; 97(10):3321-2. PubMed ID: 11368066
[No Abstract] [Full Text] [Related]
35. Management of myelodysplastic syndromes.
Sztern B; De Saint-Georges A; Telerman A; Lustman F
Am J Med; 1987 Jan; 82(1):187. PubMed ID: 3799686
[No Abstract] [Full Text] [Related]
36. Abstracts of the 7th International Symposium on Myelodysplastic Syndromes. 15-18 May 2003, Paris, France.
Leuk Res; 2003 May; 27 Suppl 1():S1-123. PubMed ID: 12713805
[No Abstract] [Full Text] [Related]
37. Abstracts of the 10th International Symposium on Myelodysplastic Syndromes. Patras, Greece. May 6-9, 2009.
Leuk Res; 2009 May; 33 Suppl 1():S1-142. PubMed ID: 19431225
[No Abstract] [Full Text] [Related]
38. Abstracts of the 9th International Symposium on Myelodysplastic Syndromes, Florence, Italy, May 16-19, 2007.
Leuk Res; 2007 May; 31 Suppl 1():S1-145. PubMed ID: 17710742
[No Abstract] [Full Text] [Related]
39. Abstracts of the 8th International Symposium on Myelodysplastic Syndromes. May 12-15, 2005, Nagasaki, Japan.
Leuk Res; 2005 May; 29 Suppl 1():S1-78. PubMed ID: 15957211
[No Abstract] [Full Text] [Related]
40. Abstracts of papers presented at the Second International Conference on Myelodysplastic Syndromes. Bournemouth, U.K., 20-23 October 1991.
Leuk Res; 1991; 15 Suppl():1-34. PubMed ID: 1682535
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
